North America Active Implantable Medical Devices Market

North America Active Implantable Medical Devices Market Size (2023 to 2028)

The size of the North America Active Implantable Medical Devices Market has been estimated at USD 8.65 billion in 2023. It is expected to reach USD 12.44 billion by 2028, registering a CAGR of 7.53% between 2023 to 2028.

The growth for active implantable medical devices in the North American region is growing due to the increasing prevalence of cardiovascular disease (CVD) and neurological disorders. CVD is primarily seen in the elderly, who are more susceptible to various ailments. The number of people aged 65 and over is expected to increase from 530 million in 2012 to nearly 1.65 billion in 2050, representing around 18% of the world's population. Implantable defibrillators and pacemakers are the primary medical devices used to treat various cardiovascular conditions, one of the leading causes of death across the globe. According to the World Health Organization, around 18 million people worldwide died from cardiovascular disease in 2014, and the numbers are expected to grow to 25 million by 2030. The increasing prevalence of cardiovascular diseases in Latin America has led to demand for technologically advanced products. According to the American College of Cardiology, CVD caused 900,000 deaths in the United States in 2019. Among Americans, an average person dies from cardiovascular disease every 45 seconds. These devices are placed near the heart and under the skin to act as artificial transvenous defibrillators and pacemakers etc., these are anticipated to help drive the market. The implantable pacemaker segment is growing rapidly, driven by increasing R&D funding for healthcare and increasing R&D trends in emerging economies of North America.

The increasing prevalence of chronic pain disorders and neuromuscular diseases, such as neuropathic pain, Parkinson's disease, Alzheimer's disease, diabetic neuropathy, etc., dramatically increases the demand for neurostimulator devices. The demand for such medical devices is anticipated to drive the market to new heights during the projected period. According to the Alzheimer's Association, approximately 5.5 million people aged 65 and over were thought to have Alzheimer's disease in 2016 in the United States. These figures are expected to reach 7.3 million in 2027 and around 13.9 million in 2050. Almost 15% of the population is over 65 and mainly needs these active implantable devices such as deep brain stimulators. In addition, the high incidence of neurological disorders is fueling demand for neurostimulators, further boosting the active market for implantable medical devices market in North America.

However, unfavorable reimbursement programs, issues with implantable medical devices, and the high cost of implants and associated surgeries may dampen the growth rate of the North American active implantable medical devices market.

This research report on North American Active Implantable Medical Devices Market has been segmented and sub-segmented into the following categories:

By Product:

• Implantable Cardioverter Defibrillators
  • Transvenous Implantable Cardioverter Defibrillators
    • Biventricular Implantable Cardioverter Defibrillators (ICDs)/Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
    • Dual-Chamber Implantable Cardioverter Defibrillators
    • Single-Chamber Implantable Cardioverter Defibrillators
  • Subcutaneous Implantable Cardioverter Defibrillator
• Implantable Cardiac Pacemakers
• Ventricular Assist Devices
• Implantable Heart Monitors/Insertable Loop Recorders
• Neurostimulators
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Gastric Electrical Stimulators
• Implantable Hearing Devices
  • Active Hearing Implants
  • Passive Hearing Implants

By Country:

• The United States
• Canada
• Rest of North America

Based on region, North America held the largest share in the regional segment of the market. The large share of this regional segment can be credited to the growth in the geriatric population, the surge in the occurrence of cardiovascular and neurological diseases, high accessibility to advanced technologies, rise in the development of innovative and technologically advanced products, and increase in the healthcare expenditure in the region.

In 2020, the United States dominated the North American active implantable medical devices market. The market is set to grow at a CAGR of 5%, attributed to the growth of the senior population, the increased prevalence of cardiovascular and neurological diseases, the high accessibility to advanced technologies, and the increased health spending in the region. According to the American Heart Association estimates, approximately 5.8 million adults in the United States suffer from congestive heart failure. In addition, according to Parkinson Disease Foundation, about 65,000 new cases of Parkinson's disease are reported annually in the United States. An increase in this disease will be responsible for the growth of the market.

However, Canada is expected to experience a healthy growth rate during the forecast period. The growth of this regional market can be attributed to the development of the senior population, the increasing incidence of chronic diseases, awareness about chronic diseases, favorable healthcare expenditure, the better healthcare infrastructure, growing competition with the United States in terms of market distribution, the availability of advanced technologies and less stringent regulations to develop high-end products and their approvals.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the North America Active Implantable Medical Devices Market profiled in the report are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC., Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd.